Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Operating Income of -$104.02 million for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$104.02M | +27.0% |
| 2024 | -$142.47M | +16.3% |
| 2023 | -$170.28M | -33.6% |
| 2022 | -$127.44M | -52.5% |
| 2021 | -$83.56M | -91.4% |
| 2020 | -$43.66M | -127.6% |
| 2019 | -$19.18M | -40.2% |
| 2018 | -$13.68M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.53M | +30.8% | +15.4% |
| June 30, 2025 | -$26.65M | +35.8% | +16.3% |
| March 31, 2025 | -$31.82M | +15.7% | +2.3% |
| September 30, 2024 | -$32.57M | +38.9% | +21.6% |
| June 30, 2024 | -$41.52M | -12.9% | -10.0% |
| March 31, 2024 | -$37.76M | -17.3% | +29.1% |
| September 30, 2023 | -$53.27M | -45.2% | -44.9% |
| June 30, 2023 | -$36.78M | -8.8% | -14.2% |
- ALX ONCOLOGY HOLDINGS INC showed an increase of +27.0% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, ALX ONCOLOGY HOLDINGS INC’s operating income has declined by 660.2% (from -$13.68 million to -$104.02 million).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: